US stock futures edge lower after S&P 500 hits record high; PCE data in focus
On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Ascendis Pharma (NASDAQ:ASND) shares with a $200.00 price target, well above the current trading price of $151.25. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $192 to $288. The firm’s analyst highlighted the upcoming second-quarter results of the Phase 2 COACH trial in Achondroplasia (ACH) as a potential significant catalyst for the biopharmaceutical company. The trial results are anticipated to be released in June, as indicated by recruitment information found on clinicaltrials.gov.
The analyst’s evaluation of previous trials suggests that the 26-week topline data of the combination therapy, which includes TransCon CNP and TransCon GH, is expected to demonstrate superior efficacy in terms of linear growth. The outcomes could potentially show an annualized growth velocity (AGV) of 8-9 centimeters per year, which would surpass the current investor expectations of 7-8 centimeters per year AGV.
Ascendis Pharma, with a market capitalization of $9.1 billion, is focused on developing a pipeline of products that address significant unmet medical needs. The company’s innovative TransCon technology is at the core of its product development strategy. While InvestingPro analysis shows the company maintains a moderate debt level and impressive gross profit margin of 85.3%, it currently operates at a loss. This technology is designed to create new therapies that optimize therapeutic effect, including best-in-class growth hormone therapies for children with growth hormone deficiency.
The potential success of the COACH trial could also lead to increased valuation for the company’s other products, Skytrofa and CNP. According to the analyst from Cantor Fitzgerald, a positive trial outcome could result in a share price increase of more than 10% in a bull case scenario.
Investors are keeping a close watch on Ascendis Pharma as the expected trial results approach. The company’s stock performance in the coming months may be significantly influenced by the COACH trial data and its implications for the company’s growth hormone treatment portfolio. Despite recent volatility, with the stock dropping 11.4% in the past week, the company has demonstrated strong revenue growth of 12.1% over the last twelve months. For deeper insights into Ascendis Pharma’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
In other recent news, Ascendis Pharma’s first-quarter results have exceeded expectations, driving analysts to adjust their projections and price targets. JPMorgan raised its price target for the company to $245, highlighting a notable revenue of €44.7 million from Yorvipath™, which was significantly higher than anticipated. Evercore ISI also increased its target to $280, citing strong prescription growth and successful transitions to paid drug conversions. Meanwhile, RBC Capital initiated coverage with a $205 target, noting Ascendis Pharma’s advantageous market position and potential peak sales for Yorvipath. UBS maintained a Buy rating with a $196 target, projecting strong performance for Yorvipath as reimbursement processes improve.
Cantor Fitzgerald adjusted its price target to $200, reflecting the impressive prescription numbers for Yorvipath and an upward revision of revenue projections. Despite an expected rise in operating expenses for 2025, Cantor Fitzgerald remains optimistic about the company’s growth. The firm’s analysts have expressed confidence in Ascendis Pharma’s trajectory, supported by the company’s robust financial performance and market response to its products. These developments indicate a positive outlook from several major analyst firms, emphasizing Ascendis Pharma’s potential for continued growth and success in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.